Corporate Development

Since our founding, Geron has focused on strong science and the pursuit of R&D excellence to discover and develop innovative, first-in-class therapies for the treatment of cancer as evidenced through the collaborative development of our first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

To contact our Corporate Development team, please send an e-mail to corpdev@geron.com.